Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.892408 Oncology Correction Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach Tai Yee Kit 1 2 Chan Karen Ka Wing 1 2 Fong Charlene Hui Hua 1 2 Ramanan Sharanya 1 2 Yap Jasmine Lye Yee 1 2 Yin Jocelyn Naixin 1 2 Yip Yun Sheng 3 Tan Wei Ren 3 Koh Angele Pei Fern 4 Tan Nguan Soon 3 5 Chan Ching Wan 6 7 Huang Ruby Yun Ju 4 8 Li Jing Ze 1 Fröhlich Jürg 1 9 10 Franco-Obregón Alfredo 1 2 11 12 13 14 * 1 Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 2 Biolonic Currents Electromagnetic Pulsing Systems Laboratory (BICEPS), National University of Singapore, Singapore, Singapore 3 Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore 4 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore 5 School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore 6 Division of General Surgery (Breast Surgery), Department of Surgery, National University Hospital, Singapore, Singapore 7 Division of Surgical Oncology, National University Cancer Institute, Singapore, Singapore 8 Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 9 Fields at Work GmbH, Zürich, Switzerland 10 Institute of Electromagnetic Fields, ETH Zürich (Swiss Federal Institute of Technology in Zürich), Zürich, Switzerland 11 Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore, Singapore 12 Competence Center for Applied Biotechnology and Molecular Medicine, University of Zürich, Zürich, Switzerland 13 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 14 Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Edited and reviewed by: Tarik Smani, Sevilla University, Spain

*Correspondence: Alfredo Franco-Obregón, suraf@nus.edu.sg

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

 20 04 2022 2022 12 892408 09 03 2022 31 03 2022 Copyright © 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach By Tai YK, Ramanan S, Chan KKW, Yap JLY, Fong CHH, Yin JN, Tan WR, Koh APF, Tan NS, Yip YS, Chan CW, Huang RYJ, Li JZ, Fröhlich J and Franco-Obregón A (2022) Front. Oncol. 11:783803. doi: 10.3389/fonc.2021.783803 breast cancer PEMFs EMT patient-derived xenograft chorioallantoic membrane doxorubicin TRPC1 chemotherapy

In the original article, there was a nonconsequential error in Figure 1 as published. A file concatenation error occurred within the FACS analysis software that implicated the scatter dot-plots shown in Figure 1C . The corrected Figure 1 appears below.

PEMFs synergize with DOX to inhibit tumor growth in vivo. (A) Schematic of PEMF and DOX exposure regimes used on mice hosting patient-derived tumor xenografts. Implanted tumors were allowed to grow for 3 weeks before the initiation of DOX (20 mg/kg) and/or PEMF treatments. Tumor volumes were measured each week while apoptotic cell determination was performed at the end of the study. Each data point represents the mean values from 5 experimental runs derived from the tumors obtained from 5 patients, each of which was equally divided amongst the 5 treatment groups. (B) Changes in tumor volume (mm3) for 5 weeks. (C) Representative scatter dot-plots showing cell populations from dissociated tumors based on Annexin V and propidium iodide staining. (D) Quantification of apoptotic cell percentages obtained using flow cytometry. *p < 0.05, **p < 0.01, and # p < 0.0001. Error bars represent the standard error of the mean.

The associated corrected values that appear in the text of the Results under the subheading “PEMF and Doxorubicin Treatments Act Synergistically to Impair Breast Cancer Tumor Growth In Vivo”, paragraph one, should read “Moreover, the incidence of apoptotic cells increased by +0.55%, +10.2%, and +18% in tumors isolated from control, PEMF-exposed and DOX-treated mice, respectively ( Figures 1C, D )”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.